Curaleaf (CURA) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
13 Jan, 2026Opening remarks and agenda
Meeting held virtually to enhance accessibility and shareholder engagement, with ground rules set for orderly conduct and participation.
Only registered shareholders and proxy holders as of April 29, 2025, could participate, vote, and ask questions.
The agenda included presentation of financial statements, board elections, auditor appointment, and a Q&A session.
Board and executive committee updates
Six directors were nominated for re-election, with two current directors retiring at the conclusion of the meeting.
The board size was set at 10, with discretion to appoint four additional directors to fill vacancies until the next AGM.
Nominees included Boris Jordan, Joseph Lusardi, Karl Johansson, Mitchell Kahn, Shasheen Shah, and Michelle Bodner.
Overview of voting outcomes
The number of directors was set at 10, and all six nominees were elected to the board.
PKF O'Connor Davies LLP was appointed as auditor, with the board authorized to fix their remuneration.
Latest events from Curaleaf
- Q4 revenue hit $333M, margins improved, and international growth accelerated despite pricing pressure.CURA
Q4 202526 Feb 2026 - Board size set at 10, all directors and auditor approved, with no questions from shareholders.CURA
AGM 20243 Feb 2026 - Q2 revenue up 2% to $342M, with 78% international growth and 48% adjusted gross margin.CURA
Q2 20242 Feb 2026 - Q3 saw stable revenue, margin gains, and 82% international growth amid U.S. market pressures.CURA
Q3 202416 Jan 2026 - 2024 revenue flat at $1.34B; international sales up 73% and margins improved.CURA
Q4 202423 Dec 2025 - International growth and product launches offset U.S. price pressure, driving Q2 results.CURA
Q2 202523 Nov 2025 - Q1 revenue fell 6% to $310M, but gross margin rose to 50% amid strong international growth.CURA
Q1 202517 Nov 2025 - Q3 revenue up 2% sequentially to $320M; international growth and margin gains offset price pressure.CURA
Q3 20256 Nov 2025